Stay updated on MEDI0680 + Durvalumab vs Nivolumab in Advanced Malignancies Clinical Trial
Sign up to get notified when there's something new on the MEDI0680 + Durvalumab vs Nivolumab in Advanced Malignancies Clinical Trial page.

Latest updates to the MEDI0680 + Durvalumab vs Nivolumab in Advanced Malignancies Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check14 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check21 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.6%
- Check29 days agoNo Change Detected
- Check50 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check64 days agoChange DetectedThe page has been updated to include a new version number (v2.15.0) and a specific selection for advanced malignancies related to kidney cancer, while significant details about the study, including the principal investigators and inclusion/exclusion criteria, have been removed.SummaryDifference6%
- Check72 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
Stay in the know with updates to MEDI0680 + Durvalumab vs Nivolumab in Advanced Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MEDI0680 + Durvalumab vs Nivolumab in Advanced Malignancies Clinical Trial page.